COVID-19 REMDESIVIR TREATMENT
This 3-day, IV delivered protocol is available, but is only effective when started within 7 days of the onset of COVID-19 symptoms.
Remdesivir is a nucleotide prodrug of an adenosine analog. A 3-day protocol is delivered intravenously.
Remdesivir binds to the viral RNA-dependent RNA polymerase and inhibits viral replication by terminating RNA transcription prematurely.
Remdesivir has demonstrated in vitro and in vivo activity against SARS-CoV-2.1 Remdesivir retains in vitro neutralization activity against the Omicron variant and its subvariants.2-5